3352-69-0|4-Desacetylvinblastine|4-Desacetylvinblastine|-范德生物科技公司

4-Desacetylvinblastine

NMR下载 COA and HPLC MSDS下载
names：
4-Desacetylvinblastine
CAS号：
3352-69-0
MDL Number：
MF(分子式)： C44H56N4O8 MW(分子量)： 768.95
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	methyl (3aR,3a1R,4R,5S,5aR)-3a-ethyl-9-((5S,7S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-4,5-dihydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate
英文别名	4-Desacetylvinblastine; Deacetylvinblastine; Desacetylvinblastine; 4-Desacetyl Vinblastine
CAS号	3352-69-0
SMILES	CC[C@@]1(C[C@@H]2C[C@@](c3c(c4ccccc4[nH]3)CCN(C2)C1)(c5cc6c(cc5OC)N([C@@H]7C68CCN9[C@H]8[C@@](C=CC9)([C@H]([C@@]7(C(=O)OC)O)O)CC)C)C(=O)OC)O
Inchi	1S/C44H56N4O8/c1-7-40(52)22-26-23-43(38(50)55-5,34-28(14-18-47(24-26)25-40)27-12-9-10-13-31(27)45-34)30-20-29-32(21-33(30)54-4)46(3)36-42(29)16-19-48-17-11-15-41(8-2,35(42)48)37(49)44(36,53)39(51)56-6/h9-13,15,20-21,26,35-37,45,49,52-53H,7-8,14,16-19,22-25H2,1-6H3/t26-,35+,36-,37-,40+,41-,42?,43+,44+/m1/s1
InchiKey	NDMPLJNOPCLANR-SAYSVMKTSA-N
分子式 Formula	C44H56N4O8
分子量 Molecular Weight	768.95
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	4-Desacetylvinblastine(CAS:3352-69-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	4-Desacetylvinblastine is a a pro-drug of Vinblastine. An anti-tumor agent used in the treatment of prostate cancer.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Zhao R, Diop-Bove N, Goldman ID. Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression. Mol Pharmacol. 2014 Feb;85(2):310-2[1] doi: 10.1124/mol.113.089110. Epub 2013 Nov 18. PubMed PMID: 24249723; PubMed Central PMCID: PMC3913358.

[2]Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 2009 Dec;49(12):1467-76. doi: 10.1177/0091270009339740. Epub 2009 Oct 16. PubMed PMID: 19837906; PubMed Central PMCID: PMC3807256.

[3] Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part

[4]EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5093-6. Epub 2006 Jul 25. PubMed PMID: 16870437.

[5] Gutowski MC, Fix DV, Corvalan JR, Johnson DA. Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody. Cancer Invest. 1995;13(4):370-4. PubMed PMID: 7627723.

5: Hilselberger Kanitz M, Mastro JM, Moore RE, Starling JJ. In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids. Anticancer Res. 1994 May-Jun;14(3A):857-68. PubMed PMID: 7915508.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开